In contentious three days of hearing on the Affordable Care Act, the Supreme Court now seems far more likely to overturn the landmark legislation.
Guest blog written by Reid Paul.
In contentious three days of hearing on the Affordable Care Act, the Supreme Court now seems far more likely to overturn the landmark legislation. Given the strong support the bill originally received from the industry, does overturning it benefit or hurt pharma?
Video: Pharma and the Supreme Court reconsider healthcare reform